Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments

Published:2021-05-03 Issue:1 Volume:5 Page:
ISSN:2573-8348
Container-title:Cancer Reports
language:en
Short-container-title:Cancer Reports

Author:

Nawa Hideki¹^ORCID,Niimura Takahiro²,Yagi Kenta³^ORCID,Goda Mitsuhiro⁴,Zamami Yoshito²⁴,Ishizawa Keisuke²⁴

Affiliation:

1. Department of Pharmacy, Faculty of Pharmacy Shujitsu University Okayama Japan

2. Department of Clinical Pharmacology and Therapeutics Tokushima University Graduate School of Biomedical Sciences Tokushima Japan

3. Clinical Research Center for Developmental Therapeutics Tokushima University Hospital Tokushima Japan

4. Department of Pharmacy Tokushima University Hospital Tokushima Japan

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cnr2.1402

Reference22 articles.

1. Palbociclib and Letrozole in Advanced Breast Cancer

2. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

3. Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

4. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study;BMC Pharmacology and Toxicology;2024-08-09

2. Cross-Cancer Type Evaluation of Potential Interstitial Lung Disease Complications of Immune Checkpoint Inhibitors Using JADER;Biological and Pharmaceutical Bulletin;2024-07-13

3. Post-Marketing Safety Concerns With Palbociclib A Disproportionality Analysis of the FDA Adverse Event;2023-08-14

4. Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel;Drug Safety;2023-08-08

5. Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment;Drug Safety;2023-07-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3